Posts
- OmniComm Systems Signs Five-Year, Multi-Million Dollar TrialMaster EDC Agreement with CROMSOURCE
- CROMSOURCE Expands Operational Footprint and Management Team
- CROMSOURCE Expansion Medical Services CMO
- CROMSOURCE Continues Strong US Growth with Multiple New Business Awards
- CROMSOURCE Celebrates its 20th Anniversary
- CROMSOURCE Regulatory Team to Present at TOPRA’s Clinical Evaluation of Medical Devices Masterclass
- CROMSOURCE Offers Clients One Trial One Price™ Guarantee
- CROMSOURCE Unveils New TalentSource Life Sciences Department Logo
- CROMSOURCE Appoints Director of Regulatory Services and Expands Regulatory Operations
- CROMSOURCE Regulatory Newsletter January – March 2019
- CROMSOURCE Regulatory Newsletter April – June 2019
- Penta and CROMSOURCE Announce their Partnership to Improve Paediatric Drug Development
- CROMSOURCE Continues US Growth with New Office in Research Triangle Park
- CROMSOURCE Consolidates its Hybrid Services Model
- CROMSOURCE Regulatory Newsletter July – September 2019
- CROMSOURCE announces a significant milestone in digital management of its projects in cooperation with TECHORIZON
- CROMSOURCE Announces Launch of COVID-19 Clinical Trial
- CROMSOURCE Regulatory Newsletter January – March 2020
- CROMSOURCE Regulatory Newsletter April – June 2020
- CROMSOURCE Regulatory Newsletter July – September 2020
- CROMSOURCE Consolidates Strategic Site Support Service
- CROMSOURCE Regulatory Newsletter October – December 2020
- CROMSOURCE Regulatory Newsletter January – March 2021
- CROMSOURCE Announces Appointment of Kris O’Brien as Global Head of TalentSource Life Sciences
- Dialco Medical Inc. Engages CROMSOURCE as CRO Partner for DIMI IDE Trial
- CROMSOURCE Regulatory Newsletter April – June 2021
- CROMSOURCE Regulatory Newsletter July – September 2021
- CROMSOURCE Regulatory Newsletter October 2021 – January 2022
- CROMSOURCE Regulatory Newsletter January – March 2022
- CROMSOURCE Celebrates 25 Years – Dedicated to Clinical Research Solutions since 1997
- CROMSOURCE Regulatory Newsletter April – June 2022
- CROMSOURCE Regulatory Newsletter July – September 2022
- CROMSOURCE Regulatory Newsletter October – December 2022
- Stayble Therapeutics receives approval to start Phase Ib clinical trial with STA363 for the treatment of herniated discs
- ClinChoice Acquires CROMSOURCE, Expanding its Global Presence
- CROMSOURCE Regulatory Newsletter January – March 2023
